Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma
…, P Simon, D Schallier, C Fontaine… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Human epidermal growth factor receptor 2 (HER2) status is one of the major tumor characteristics
in breast cancer to guide therapy. Anti-HER2 treatment has clear survival advantages …
in breast cancer to guide therapy. Anti-HER2 treatment has clear survival advantages …
Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports
J Caers, C Fontaine, V Vinh-Hung, J De Mey… - Supportive Care in …, 2005 - Springer
Aims The use of subcutaneous infusion ports has become standard practice to provide a
long-term venous access in oncological patients. The aim of this retrospective study was to …
long-term venous access in oncological patients. The aim of this retrospective study was to …
Are Socioeconomic Benefits of Restoration Adequately Quantified? A Meta‐analysis of Recent Papers (2000–2008) in Restoration Ecology and 12 Other Scientific …
…, KJ Esler, A Limouzin, C Fontaine… - Restoration …, 2010 - Wiley Online Library
Many ecosystems have been transformed, or degraded by human use, and restoration
offers an opportunity to recover services and benefits, not to mention intrinsic values. We …
offers an opportunity to recover services and benefits, not to mention intrinsic values. We …
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics
PURPOSE: To investigate the safety and pharmacokinetics (PK) of combined treatment with
letrozole and the oral mTOR inhibitor RAD001 in patients with metastatic breast cancer …
letrozole and the oral mTOR inhibitor RAD001 in patients with metastatic breast cancer …
Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients
…, J Heemskerk, FP Duhoux, C Fontaine… - Journal of Nuclear …, 2021 - Soc Nuclear Med
131 I-GMIB-anti-human epidermal growth factor receptor type 2 (HER2)-VHH1 is a targeted
radionuclide theranostic agent directed at HER2-expressing cancers. VHH1 is a single-…
radionuclide theranostic agent directed at HER2-expressing cancers. VHH1 is a single-…
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue …
…, S Sleijfer, P Wolter, I Ray-Coquard, C Fontaine… - European journal of …, 2010 - Elsevier
AIMS: BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1. We
performed a multi-centre, multi-tumour phase II trial to investigate the efficacy, safety and …
performed a multi-centre, multi-tumour phase II trial to investigate the efficacy, safety and …
[HTML][HTML] Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis
…, H Wildiers, A Laenen, S Aspeslagh, C Fontaine… - ESMO open, 2020 - Elsevier
Background Cancer seems to have an independent adverse prognostic effect on COVID-19-related
mortality, but uncertainty exists regarding its effect across different patient subgroups…
mortality, but uncertainty exists regarding its effect across different patient subgroups…
Phase I study of [68Ga] Ga-Anti-CD206-sdAb for PET/CT assessment of protumorigenic macrophage presence in solid tumors (MMR phase I)
…, Q Lecocq, L Decoster, C Fontaine… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Macrophages play an important role throughout the body. Antiinflammatory macrophages
expressing the macrophage mannose receptor (MMR, CD206) are involved in disease …
expressing the macrophage mannose receptor (MMR, CD206) are involved in disease …
[HTML][HTML] Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast …
…, B Caljon, I Pauwels, M Bonduelle, S Joris, C Fontaine… - BMC cancer, 2019 - Springer
Background In the majority of familial breast cancer (BC) families, the etiology of the disease
remains unresolved. To identify missing BC heritability resulting from relatively rare variants …
remains unresolved. To identify missing BC heritability resulting from relatively rare variants …
[HTML][HTML] Towards precision pain medicine for pain after cancer: The Cancer Pain Phenotyping Network multidisciplinary international guidelines for pain phenotyping …
…, P Madeleine, C Fontaine… - British Journal of …, 2023 - Elsevier
Pain after cancer remains underestimated and undertreated. Precision medicine is a recent
concept that refers to the ability to classify patients into subgroups that differ in their …
concept that refers to the ability to classify patients into subgroups that differ in their …